Recombinant Human Granulocyte Colony-stimulating Factor（rhG-CSF）
- Generic Name
- Recombinant Human Granulocyte Colony-stimulating Factor（rhG-CSF）
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于：1.各种原因引起的中性粒细胞减少证，如恶性肿瘤和白血病化疗与放疗引起的中性粒细胞减少、造血干/祖细胞移植后髓系造血功能的受抑及延迟植活鱼移植排斥；
2.周围血造血干/祖细胞移植前的干/祖细胞动员等；
3.骨髓增生异常综合征（MDS）、再生障碍性贫血伴发的中性粒细胞减少，先天性、特发性、周期性中性粒细胞减少症，但远期疗效不肯定；
4.各种严重感染，包括艾滋病及并发的感染；
5.抗艾滋病药物引起的中性粒细胞减少症也可应用。
- Associated Conditions
- -
- Associated Therapies
- -
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-07-17
- Target Recruit Count
- 30
- Registration Number
- NCT06504901
The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Trio Fertility
- Target Recruit Count
- 30
- Registration Number
- NCT06117982
- Locations
- 🇨🇦
Trio Fertility, Toronto, Ontario, Canada
Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Chongqing University Cancer Hospital
- Target Recruit Count
- 174
- Registration Number
- NCT06026995
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Ou Bai, MD/PHD
- Target Recruit Count
- 144
- Registration Number
- NCT05834751
- Locations
- 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 80
- Registration Number
- NCT05156554
Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Chongqing University Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04542356
- Locations
- 🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2020-08-05
- Target Recruit Count
- 50
- Registration Number
- NCT04500886
- Locations
- 🇨🇳
Beijing Friendship Hospital, Beijing, China
Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 170
- Registration Number
- NCT04460508
- Locations
- 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT04083079
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Air Force Military Medical University, China
- Target Recruit Count
- 20
- Registration Number
- NCT03206684
- Locations
- 🇨🇳
Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.